Evidence map›Paper›PMID 29264927›Full record

ArticleInternational journal of toxicology

Toxicology Evaluation of Drugs Administered via Uncommon Routes: Intranasal, Intraocular, Intrathecal/Intraspinal, and Intra-Articular.

Armaghan Emami, Jeff Tepper, Brian Short, Tony L Yaksh, Alison M Bendele, Thulasi Ramani, Alvaro F Cisternas, Jay H Chang, R Daniel Mellon

Abstract read
In one paragraph

Article in International journal of toxicology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Trial
  2. Article
  3. Divalent siRNA for prion disease.Nucleic acids research · 2026
    Article
  4. Divalent siRNA for prion disease.bioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. Article
  7. Chronic, combinatorial targeting of NMDARs and 5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Armaghan Emami1 US Food and Drug Administration, Silver Spring, MD, USA.
Jeff Tepper2 Tepper Nonclinical Consulting, San Carlos, CA, USA.
Brian Short3 Brian Short Consulting, LLC, Trabuco Canyon, CA, USA.
Tony L Yaksh4 Department of Anesthesiology, University of California, San Diego, La Jolla, CA, USA.
Alison M Bendele5 Bolder BioPATH Inc, Boulder, CO, USA.
Thulasi Ramani6 Envigo, Somerset, NJ, USA.
Alvaro F Cisternas7 Sorrento Therapeutics Inc, San Diego, CA, USA.
Jay H Chang1 US Food and Drug Administration, Silver Spring, MD, USA.
R Daniel Mellon1 US Food and Drug Administration, Silver Spring, MD, USA.

Funding

Characterization of Toxicity with Spinal OpiatesR01DA015353 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YAKSH, TONY L. · 2003 to 2017
$4.4M
NIDA NIH HHS R01 DA015353
6 · The paper itself

Abstract

As the need for nasal, ocular, spinal, and articular therapeutic compounds increases, toxicology assessments of drugs administered via these routes play an important role in human safety. This symposium outlined the local and systemic evaluation to support safety during the development of these drugs in nonclinical models with some case studies. Discussions included selection of appropriate species for the intended route; conducting nonclinical studies that closely mimic the intended use with adequate duration; functional assessment, if deemed necessary; evaluation of local tissues with special histological staining procedure; and evaluations of safety margins based on local and systemic toxicity.

Indexed as

Drug-Related Side Effects and Adverse ReactionsAdministration, IntranasalHumansInjections, Intra-ArticularInjections, IntraocularInjections, SpinalPharmaceutical PreparationsPharmaceutical Preparationsanalgesicsantispasticityepiduralgranulomaintra-articularintracameralintranasalintrathecalintravitreallocal toxicitysafety evaluationsafety marginsspinal cordtoxicity

Identifiers

PMID29264927
PMCPMC5874330

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.